88 related articles for article (PubMed ID: 27383882)
1. Development of molecules stimulating the activity of KLK3 - an update.
Koistinen H; Wallén E; Ylikangas H; Meinander K; Lahtela-Kakkonen M; Närvänen A; Stenman UH
Biol Chem; 2016 Dec; 397(12):1229-1235. PubMed ID: 27383882
[TBL] [Abstract][Full Text] [Related]
2. Virtual Screening of Small Drug-Like Compounds Stimulating the Enzymatic Activity of Kallikrein-Related Peptidase 3 (KLK3).
Ylikangas H; Mattsson JM; Stenman UH; Koistinen H; Poso A; Lahtela-Kakkonen M
ChemMedChem; 2016 Sep; 11(18):2043-9. PubMed ID: 27465435
[TBL] [Abstract][Full Text] [Related]
3. Peptides binding to prostate-specific antigen enhance its antiangiogenic activity.
Mattsson JM; Närvänen A; Stenman UH; Koistinen H
Prostate; 2012 Oct; 72(14):1588-94. PubMed ID: 22430591
[TBL] [Abstract][Full Text] [Related]
4. Development of peptides specifically modulating the activity of KLK2 and KLK3.
Koistinen H; Närvänen A; Pakkala M; Hekim C; Mattsson JM; Zhu L; Laakkonen P; Stenman UH
Biol Chem; 2008 Jun; 389(6):633-42. PubMed ID: 18627344
[TBL] [Abstract][Full Text] [Related]
5. KLK3 in the Regulation of Angiogenesis-Tumorigenic or Not?
Koistinen H; Künnapuu J; Jeltsch M
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948344
[TBL] [Abstract][Full Text] [Related]
6. Proteolytic activity of prostate-specific antigen (PSA) towards protein substrates and effect of peptides stimulating PSA activity.
Mattsson JM; Ravela S; Hekim C; Jonsson M; Malm J; Närvänen A; Stenman UH; Koistinen H
PLoS One; 2014; 9(9):e107819. PubMed ID: 25237904
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer.
LeBeau AM; Kostova M; Craik CS; Denmeade SR
Biol Chem; 2010 Apr; 391(4):333-43. PubMed ID: 20180648
[TBL] [Abstract][Full Text] [Related]
8. The discovery of compounds that stimulate the activity of kallikrein-related peptidase 3 (KLK3).
Härkönen HH; Mattsson JM; Määttä JA; Stenman UH; Koistinen H; Matero S; Windshügel B; Poso A; Lahtela-Kakkonen M
ChemMedChem; 2011 Dec; 6(12):2170-8. PubMed ID: 21953896
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic properties of prostate-specific antigen (PSA).
Mattsson JM; Laakkonen P; Stenman UH; Koistinen H
Scand J Clin Lab Invest; 2009; 69(4):447-51. PubMed ID: 19551556
[TBL] [Abstract][Full Text] [Related]
10. Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus.
Lawrence MG; Lai J; Clements JA
Endocr Rev; 2010 Aug; 31(4):407-46. PubMed ID: 20103546
[TBL] [Abstract][Full Text] [Related]
11. Mimetics of the disulfide bridge between the N- and C-terminal cysteines of the KLK3-stimulating peptide B-2.
Pakkala M; Weisell J; Hekim C; Vepsäläinen J; Wallen EA; Stenman UH; Koistinen H; Närvänen A
Amino Acids; 2010 Jun; 39(1):233-42. PubMed ID: 19967419
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of peptides as protease inhibitors and stimulators.
Koistinen H; Hekim C; Wu P; Närvänen A; Stenman UH
Methods Mol Biol; 2014; 1088():147-58. PubMed ID: 24146402
[TBL] [Abstract][Full Text] [Related]
13. Epithelial-mesenchymal transition in prostate cancer and the potential role of kallikrein serine proteases.
Lawrence MG; Veveris-Lowe TL; Whitbread AK; Nicol DL; Clements JA
Cells Tissues Organs; 2007; 185(1-3):111-5. PubMed ID: 17587816
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of human prostate-specific antigen in a sandwich antibody complex.
Stura EA; Muller BH; Bossus M; Michel S; Jolivet-Reynaud C; Ducancel F
J Mol Biol; 2011 Dec; 414(4):530-44. PubMed ID: 22037582
[TBL] [Abstract][Full Text] [Related]
15. Novel small molecule inhibitors for prostate-specific antigen.
Koistinen H; Wohlfahrt G; Mattsson JM; Wu P; Lahdenperä J; Stenman UH
Prostate; 2008 Aug; 68(11):1143-51. PubMed ID: 18500692
[TBL] [Abstract][Full Text] [Related]
16. Replacement of the Disulfide Bridge in a KLK3-Stimulating Peptide Using Orthogonally Protected Building Blocks.
Meinander K; Pakkala M; Weisell J; Stenman UH; Koistinen H; Närvänen A; Wallén EA
ACS Med Chem Lett; 2014 Feb; 5(2):162-5. PubMed ID: 24900791
[TBL] [Abstract][Full Text] [Related]
17. Seminal fluid characterization for male fertility and prostate cancer: kallikrein-related serine proteases and whole proteome approaches.
Veveris-Lowe TL; Kruger SJ; Walsh T; Gardiner RA; Clements JA
Semin Thromb Hemost; 2007 Feb; 33(1):87-99. PubMed ID: 17253195
[TBL] [Abstract][Full Text] [Related]
18. Structural model of human PSA: a target for prostate cancer therapy.
Hassan MI; Kumar V; Singh TP; Yadav S
Chem Biol Drug Des; 2007 Sep; 70(3):261-7. PubMed ID: 17718721
[TBL] [Abstract][Full Text] [Related]
19. Gene expression changes associated with the anti-angiogenic activity of kallikrein-related peptidase 3 (KLK3) on human umbilical vein endothelial cells.
Mattsson JM; Laakkonen P; Kilpinen S; Stenman UH; Koistinen H
Biol Chem; 2008 Jun; 389(6):765-71. PubMed ID: 18627292
[TBL] [Abstract][Full Text] [Related]
20. Development of novel peptide ligands modulating the enzyme activity of prostate-specific antigen.
Leinonen J; Wu P; Koivunen E; Närvänen A; Stenman UH
Scand J Clin Lab Invest Suppl; 2000; 233():59-64. PubMed ID: 11317943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
